The Gustave Roussy immune Score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the stupp protocol

Key Points

• The Gustave Roussy immune score predicts survival in patients with glioblastoma, highlighting its potential as a prognostic tool.
• This score reflects systemic inflammation, with significant implications for treatment strategies in glioblastoma patients.
• The study focuses on isocitrate dehydrogenase wild-type glioblastoma, a challenging subtype with notably poor prognosis.
• Using the Stupp protocol for treatment, the immune score demonstrates relevance in evaluating patient outcomes over time.